^
Association details:
Biomarker:AR splice variant 7
Cancer:Prostate Cancer
Drug:HSK38008 (AR-V7 degrader)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

LB262 / 14 - HSK38008: An oral AR-V7 degrader for metastatic castration-resistant prostate cancer

Published date:
03/15/2023
Excerpt:
HSK38008 significantly inhibit the cell proliferation in AR-V7 positive cell line, e.g., 22RV1, but weak antiproliferation in AR and ARV7 positive cell line such as VCAP However, when combination with enzalutamide there is synergistic effect for the anti-proliferation in VCAP.